

In re Appln. of Ransberger et al.  
Application No. Unassigned (U.S. National Phase of PCT/EP99/07634)

11. The method of claim 9, wherein the hyperactive T cells are contacted with rutoside.

12. The method of claim 10, wherein the hyperactive T cells are contacted with rutoside.

13. The method of claim 10, wherein the hyperactive T cells are contacted with 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin per dose unit.

14. The method of claim 12, wherein the hyperactive T cells are contacted with 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin per dose unit.

15. The method of claim 12, wherein the hyperactive T cells are contacted with 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H<sub>2</sub>O per dose unit.

16. The method of claim 13, wherein the hyperactive T cells are contacted with 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H<sub>2</sub>O per dose unit.

17. The method of claim 14, wherein the hyperactive T cells are contacted with 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H<sub>2</sub>O per dose unit.

18. The method of claim 12, wherein the hyperactive T cells are contacted with 90 mg bromelain, 48 mg trypsin and 100 mg rutoside x 3H<sub>2</sub>O per dose unit.

19. The method of claim 9, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

20. The method of claim 10, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

21. The method of claim 11, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

AI  
CM.x  
11/11/99

In re Appln. of Ransberger et al.  
Application No. Unassigned (U.S. National Phase of PCT/EP99/07634)

22. The method of claim 12, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

23. The method of claim 13, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

24. The method of claim 14, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

25. The method of claim 15, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

26. The method of claim 16, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

27. The method of claim 17, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

28. The method of claim 18, which further comprises contacting the hyperactive T cells with  $\alpha_2$ -macroglobulin.

---

#### REMARKS

The present application is the U.S. national phase of a PCT application. In the present Amendment, claims 1-8 are cancelled, and claims 9-28 are added. The claims have been amended to conform the claims to U.S. patent practice and to eliminate multiple claim dependencies. No new matter has been added by way of these amendments.

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If in the opinion of the